Results 81 to 90 of about 181,087 (306)

Cytokine Release Syndrome After Modified CAR-NK Therapy in an Advanced Non-small Cell Lung Cancer Patient: A Case Report

Cell Transplantation, 2022
Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang, Yuying Guo, Yinghua Ji, Yan Gao, Min Zhang, Yanting Liu, Wuling Zhu, Ping Lu   +7 more
doaj   +1 more source

Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review

Advances in Cancer Biology - Metastasis, 2022
Cancer is the leading cause of death globally after cardiovascular diseases. Conventional therapeutic strategies have had minimal success rate. Recently, immunotherapy, particularly chimeric antigen receptor T cells (CAR T cells), has emerged as the most
Ubaid Ahmad, Zafran Khan, Daniya Ualiyeva, Obed Boadi Amissah, Zohaib Noor, Asaf Khan, Nasib Zaman, Marwa Khan, Ayub Khan, Babar Ali   +9 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Regulation of B cell fate by chronic activity of the IgE B cell receptor. [PDF]

, 2016
IgE can trigger potent allergic responses, yet the mechanisms regulating IgE production are poorly understood. Here we reveal that IgE+ B cells are constrained by chronic activity of the IgE B cell receptor (BCR).
Allen, Christopher DC, Chen, Xiangjun, Liu, Wanli, Robinson, Marcus J, Smith, Geoffrey A, Taunton, Jack, Yang, Zhiyong   +6 more
core   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source

Engineered T Cell Therapies from a Drug Development Viewpoint

Engineering, 2019
Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life.
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey   +5 more
doaj   +1 more source

CAR-T cell. the long and winding road to solid tumors [PDF]

, 2018
Adoptive cell therapy of solid tumors with reprogrammed T cells can be considered the "next generation" of cancer hallmarks. CAR-T cells fail to be as effective as in liquid tumors for the inability to reach and survive in the microenvironment ...
A Heczey, AH Long, AM Leen, AP Cogdill, ARW Schröder, B Clémenceau, B Moldt, BD Koster, C Carpenito, C Zhang, CE Brown, CH June, CM Bollard, D Kobelt, DM Frey, DM Pardoll, DM Shayakhmetov, DW Lee, EI Buchbinder, EJ Lipson, EM Allen Van, F Bushman, F Ochi, F You, FS Hodi, G Gross, G Sconocchia, G Sconocchia, GL Beatty, H Karlsson, H Koehler, H Torikai, HC Ertl, HJ Pegram, I Caruana, J Badhiwala, J Ellis, J Wang, JE Bakema, JH Sampson, JL Tanyi, K Kono, K Kono, K Kudo, K Tamada, K Töpfer, KC Feng, L Bracci, L Zhang, LE Kandalaft, LM Rogers, LM Whilding, M Chmielewski, M Hegde, M Koneru, M Palma De, M Sadelain, M Sadelain, MA Ligtenberg, MC Milone, MCI Schalkwyk van, MD Stewart, ME Mikucki, ME Weijtens, MJ Besser, MJ Besser, MJ Butte, MJ Osborn, ML Davila, ML Davila, MM D’Aloia, MV Maus, N Ahmed, N Ahmed, O Walisko, P Kebriaei, PB Hackett, PC Schuberth, R Braster, R Monjezi, RA Morgan, RA Morgan, RJ Brentjens, RP Junghans, S Chabot, S Mohammed, S Nayak, S Sakaguchi, S Su, S Toyokuni, S Wilkie, SA Richman, SC Katz, SL Goff, SL Maude, SR Witting, SV Kulemzin, TR Medler, TR Simpson, V Arumugam, VD Fedorov, VD Sadelain, W Wang, XS Zhong, Z Eshhar, Z Grada, Z Wang   +106 more
core   +2 more sources

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source

Tisagenlecleucel Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor–T Cells

CPT: Pharmacometrics & Systems Pharmacology, 2019
Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of therapies for treating cytokine release syndrome (tocilizumab and ...
Andrew M. Stein, Stephan A. Grupp, John E. Levine, Theodore W. Laetsch, Michael A. Pulsipher, Michael W. Boyer, Keith J. August, Bruce L. Levine, Lori Tomassian, Sweta Shah, Mimi Leung, Pai‐Hsi Huang, Rakesh Awasthi, Karen Thudium Mueller, Patricia A. Wood, Carl H. June   +15 more
doaj   +1 more source

Expanding Chemical Space of Nucleic Acid Nanoparticles for Tunable Antiviral‐Like Immunomodulatory Responses and Potent Adjuvant Activity

Advanced Functional Materials, EarlyView.
We introduce a nucleic acid nanoparticle (NANP) platform designed to be rrecognized by the human innate immune system in a regulated manner. By changing chemical composition while maintaining constant architectural parameters, we identify key determinants of immunorecognition enabling the rational design of NANPs with tunable immune activation profiles
Martin Panigaj, Hannah S. Newton, Jian Wang, Laxmi Pandey, Yelixza I. Avilla, Phong Nguyen, Morgan Chandler, Justin Halman, Yasmine Radwan, Stephanie Smith, Elijah Edmondson, Simone Difilippantonio, Chelsea Sanders, Bao Tran, Yongmei Zhao, Shaojun Xie, Edward Cedrone, Barry W. Neun, Meni Wanunu, Nikolay V. Dokholyan, Marina A. Dobrovolskaia, Kirill A. Afonin   +21 more
wiley   +1 more source